Of Counsel

Sydney + 61.2.8272.0528

Anthony Muratore has more than 35 years of experience in the area of intellectual property law and is consistently recognized as one of Australia's leading patent litigators. He has established a reputation acting as the Australian member of global teams representing clients in multijurisdictional patent disputes.

Anthony has acted in a range of matters involving biotechnology, pharmaceuticals, mechanical engineering, chemistry, and information technology. In the biotechnology and health care fields, he has acted in matters involving patents relating to drug formulation, transdermal drug delivery devices, synthetic nucleotides, sterility assurance, gene silencing, photodynamic therapy, contact lenses, and CPAP for the treatment of sleep apnea.

Some of these matters are amongst Australia's most high-profile cases that have tested and established some of the most fundamental aspects of Australian patent law. These include the High Court's rulings on whether isolated nucleic acids (Myriad Genetics) and methods of treatments of human beings (Sanofi v. Apotex) are patentable subject matter under Australian law.

Currently, Anthony acts for clients in patent disputes involving key technology and blockbuster pharmaceuticals. This includes acting for AbbVie in relation to Humira, Sanofi in relation to Praluent (PCSK9), and Toolgen Inc. in relation to revolutionary CRISPR gene editing technology.

Anthony is on the WIPO list of arbitrators and is a member and past chairman of the Intellectual Property Law subcommittee of the Law Council of Australia.


  • Sanofi challenges Amgen's patent applications for anti-PCSK9 antibodies before Australian Patent OfficeJones Day is acting in an opposition proceeding for Sanofi and Regeneron in relation to their challenge to a portfolio of applications held by Amgen Inc. that claim anti-PCSK9 antibodies and their use in the treatment of hypercholesterolemia.
  • ToolGen defends revolutionary CRISPR technology patentJones Day is acting for ToolGen, Inc. in relation to a challenge to its patent rights concerning CRISPR, a technology that has revolutionized the field of molecular biology including gene editing in the medical, biotechnology, and agricultural and farming industries.
  • Idenix asserts patent infringement against Gilead in Australia related to Sovaldi® and Harvoni®Jones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in the Federal Court of Australia over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
  • Kaplan acquires Red MarkerJones Day advised Kaplan Inc. on its acquisition, acting through Kaplan Australia Pty Ltd, of all of the issued share capital of Red Marker Pty Ltd together with all vested and unvested options for shares issued by the company.
  • Bradken successfully defends patent infringement case brought by CQMS concerning mining equipmentJones Day acted for Bradken Limited in its successful defense against claims made by CQMS Pty Ltd that Bradken infringed patents concerning ground engaging tools.
  • Myriad acts in High Court's first consideration of genetic material patentsJones Day acted for Myriad Genetics, Inc. in a landmark Australian case before the High Court of Australia.
  • Australian appeal court upholds patentability of Myriad's claims to nucleic acid sequencesIn a landmark Australian case, Jones Day client Myriad Genetics, Inc., secured a victory before the Federal Court holding that Myriad's claims to isolated nucleic acids are patentable under the Patents Act 1990.